Dr. Eckhardt on the Wnt Pathway in Colorectal Cancer

Video

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

S. Gail Eckhardt, MD, professor and head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center, discusses the wnt pathway and its role in colorectal cancer.

Eckhardt says the wnt pathway is highly mutated in colorectal cancer and has been linked to the regulation of the adenomatous polyposis coli (APC) gene and stem cells.

In addition to being a target to treat colorectal cancer, Echkardt says, the wnt pathway is also an area of interest in pancreatic cancer because of the stem cell component.

As the wnt pathway is redundant and complex, Eckhardt says, a combination approach could be the most beneficial.

In pancreatic cancer, chemotherapy would be used to debulk a tumor before a stem cell-targeted wnt inhibitor is administered, Eckhardt says. In colorectal cancer, the MEK pathway and the wnt pathway are both targeted.

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai